Uburyo bwo kuvura kanseri y'igifu bwa CAR-T

Claudin18.2 (CLDN18.2) ni poroteyine ikora cyane igaragara mu gice cy’imbere cy’igifu kandi igaragara cyane ku buso bw’uturemangingo twa kanseri y’igifu. CT041 (kode y’iterambere CG4006) ni igikoresho cya CAR-T cyibanda kuri CLDN18.2. Amakuru y’icyiciro cya mbere agaragaza ko abarwayi ba kanseri y’igifu bafite CLDN18.2 bavuwe mbere y’uko bavurwa.

Uburwayi bwa HER2 bukabije bugaragara no mu itsinda ry’abarwayi ba kanseri y’igifu. Uburyo bwo kuvura bwa CAR-T bwibasiwe na HER2 bwagaragaje ubushobozi bwo kurwanya ikibyimba mu bushakashatsi bwakozwe mbere yo kuvura no mu bushakashatsi bwa mbere. TAC01-HER2 ya Triumvira Immunologics ubu iri mu igeragezwa rya kabiri.

• Intego yihariye cyane: Mu kuyobora uturemangingo twa CAR-T kuri CLDN18.2 cyangwa HER2, uturemangingo twa kanseri y'igifu dushobora kumenyekana neza no kurandurwa, bigabanye ingaruka ziterwa n'uturemangingo.

• Gutsinda Ubudahangarwa bwo Kuvura Imirongo MininiMu igeragezwa rya CT041, itsinda ry’abarwayi ba kanseri y’igifu ryageze ku gipimo cy’ubutabazi bw’ibanze (ORR) cya 57.1%, igipimo cyo kurwanya indwara (DCR) cya 75.0%, n’amezi 6 yo kubaho muri rusange (OS) cya 81.2% mu barwayi bananiwe imiti myinshi yabanje.

• Ibisubizo birambye: Ubuvuzi bwa CLDN18.2-CAR-T bwatanze igipimo cy’ubwitabire mu gihe cy’amezi 6 cya 44.8%, bigaragaza ko bushobora kugira akamaro mu buvuzi mu gihe kirekire.

• Ubuvuzi BwiteGukoresha uturemangingo twa T tw'umurwayi bigabanya ibyago byo kwangwa kandi byongera umutekano n'imikorere myiza.

• Gukusanya uturemangingo twa T tw'amaraso yo mu mpande
  Uturemangingo twa T dukurwa mu maraso y'umurwayi binyuze mu maraso ya leukapheresis.

• Ubwubatsi bw'ibinyabutabire
  Muri laboratwari ikurikiza GMP, uturemangingo twa T duhindurwamo CAR igamije CLDN18.2 cyangwa HER2, hanyuma tukaguka nyuma y’ubuzima.

• Uburyo bwo koroshya imitsi
  Gahunda yo gutegura cyclophosphamide na fludarabine iratangwa kugira ngo igabanuke lymphocytes zo mu bwoko bwa endogenous kandi itange umwanya mwiza wo kwaguka kw'uturemangingo twa CAR-T.

• Gutera Seli za CAR-T
  Uturemangingo twa CAR-T twakozwe mu buryo bwa "engineering" twongera gushyirwa mu murwayi mu mitsi.

• Igenzura n'imicungire
  Nyuma yo guterwa, abarwayi bakurikiranirwa hafi niba nta cytokine release syndrome (CRS) cyangwa uburozi bw'imitsi, kandi hagatangwa ubufasha ku gihe uko bikenewe.

• Isesengura ry'agateganyo rya CT041 (CLDN18.2-CAR-T) Icyiciro cya mbere
  Mu barwayi 37 bavuwe mbere y’uko bavurwa, itsinda rito rya kanseri y’igifu ryageze kuri ORR 57.1%, DCR 75.0%; 94.6% bahuye na CRS yo mu cyiciro cya 1-2 gusa, nta CRS yo mu cyiciro cya 3 cyangwa hejuru cyangwa uburozi bw’imitsi; igihe cy’amezi 6 cyo gusubiza cyari 44.8%.

• Ibisubizo bya nyuma bya Satri-cel (nabyo bigamije CLDN18.2) Icyiciro cya mbere
  Mu barwayi 98 ba kanseri y’igifu ya CLDN18.2, ORR yari 38.8%, DCR 91.8%; impuzandengo yo kubaho idakomeza kwiyongera (mPFS) yari amezi 4.4 (95% CI 3.7–6.6), impuzandengo yo kubaho muri rusange (mOS) yari amezi 8.8 (95% CI 7.1–10.2); 96.9% bahuye na CRS yo mu cyiciro cya 1–2 gusa, nta CRS yo mu cyiciro cya 3+ cyangwa izindi mpfu zifitanye isano.

• Amakuru ya mbere y'ubuvuzi ya HER2-CAR-T
  Inyigo ya mbere mu cyiciro cya mbere cy’abantu yagaragaje imiterere y’umutekano ishoboka; igerageza ryo kwiyandikisha mu cyiciro cya kabiri rirakomeje.

• Urubuga rw'Ikoranabuhanga Rukuru
  BIOOCUS ifite ikigo mpuzamahanga gikora ubuvuzi bw’uturemangingo bwo mu rwego rwa GMP, gitanga serivisi nziza kandi zihamye zo gukora uturemangingo twa CAR-T.

• Itsinda ry'impuguke mu nzego zitandukanye
  Itsinda ryacu ririmo inzobere mu buvuzi bw’indwara z’umubiri, kanseri, no kuvura ingirabuzima fatizo, batanga ubuvuzi bwihariye.

• Ubunararibonye Mpuzamahanga mu by'Ubuvuzi
  Twavuje abarwayi baturutse impande zose z'isi, dukusanya amakuru menshi ku mutekano n'ubushobozi bw'ubuvuzi.

• Serivisi yuzuye kuva ku mpera kugeza ku mpera
  Kuva ku gushushanya gahunda no guhuza uburyo bwo kuvura mu mahanga kugeza ku gukurikirana igihe kirekire nyuma yo gutera imiti, BIOOCUS itanga ubufasha butunguranye.